Brief: Silence Therapeutics Announces Positive Data From Gemini Phase 1 Study Of SLN124 In Healthy Volunteers

Silence Therapeutics

19/05/2021 08:09

May 19 (Reuters) - Silence Therapeutics PLC  SLN.L :
    * SILENCE THERAPEUTICS PLC - ANNOUNCES POSITIVE DATA FROM
GEMINI
PHASE 1 STUDY OF SLN124 IN HEALTHY VOLUNTEERS
    * SILENCE THERAPEUTICS PLC - - DATA SHOWED SLN124,  WAS SAFE
AND
EFFECTIVE IN REDUCING PLASMA IRON LEVELS AND HAD A LONG DURATION
OF ACTION
    * SILENCE THERAPEUTICS PLC - - DATA SUPPORT ONGOING PHASE 1
STUDY
OF SLN124 IN PATIENTS WITH THALASSEMIA AND MYELODYSPLASTIC
SYNDROME (MDS)
    * SILENCE THERAPEUTICS PLC - FIRST CLINICAL DATA FROM
SILENCE'S
PROPRIETARY MRNAI GOLD™ PLATFORM - TWO MORE CLINICAL DATA
READOUTS ANTICIPATED THIS YEAR

Source text for Eikon:  ID:nRSS0635Za 
Further company coverage:  SLN.L 

 ((Reuters.Briefs@thomsonreuters.com;))